1555 Adams Drive
169 articles with Intersect ENT
Intersect ENT, Inc. announced that it will release first quarter financial results on May 6, 2019.
Intersect ENT, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018.
Intersect ENT, Inc. announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City, and will present in a session at 9:30 a.m. ET.
Intersect ENT, Inc. announced that it will release fourth quarter and year 2018 financial results on February 25, 2019.
Revenue for the full year 2018 is expected to be in the range of $108.3 to $108.5 million, an increase of 12-13% compared to $96.3 million for 2017
Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon
Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery
Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery
Intersect ENT, Inc. today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology, the official journal of the American Rhinologic Society, of the company’s PROPEL® Contour and PROPEL® Mini steroid releasing sinus implants showing improved outcomes of frontal sinus surgery.
Intersect ENT, Inc. today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City, and will present in a session at 10:30am ET.
Total revenue grew to $24.7 million for the third quarter 2018 compared to $22.3 million for the same period of 2017, an increase of 11%.
Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer
Intersect ENT, Inc. announced that it will release third quarter financial results.
Intersect ENT, Inc. is a company dedicated to improving the quality of life for patients with ear, nose and throat conditions
Intersect ENT, Inc. announced that it will release financial results for its second quarter on August 1, 2018.
Intersect ENT, Inc. announced that management will present at the 38th Annual William Blair Growth Stock Conference.
Intersect ENT, Inc. reported financial results for the first quarter ended March 31, 2018.
Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion
Intersect ENT, Inc. reported financial results for the fourth quarter and year ended December 31, 2017.
Intersect ENT today announced that it will release financial results for its fourth quarter and year 2017 on February 27, 2018.
Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
The study authors concluded that significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that the SINUVA Sinus Implant may play an important role in management of recurrent nasal polyps.
Intersect ENT today reported preliminary unaudited revenue for the fourth quarter and year ended December 31, 2017.